Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
Nelson AJ, Kaltenbach LA, McGuire DK, Levya M, Al-Khalidi HR, Webb L, Lopes RD, Pop-Busui R, Cavender MA, Aroda VR, Magwire ML, Richardson CR, Lingvay I, Kirk JK, Pandey A, Gaynor T, Pak J, Washington A, Senyucel C, Green JB, Granger CB, Pagidipati NJ.
Nelson AJ, et al.
Am Heart J. 2024 Dec 21:S0002-8703(24)00336-3. doi: 10.1016/j.ahj.2024.12.006. Online ahead of print.
Am Heart J. 2024.
PMID: 39716628